Purgo Scientific is a medical device company that develops localized, sustained drug delivery devices designed to treat orthopedic biofilm infections and fracture-related infections. Their lead preclinical product, the Purgo Pouch, is a combination product intended to sustain local antibiotic therapy, kill biofilms, and expedite wound healing.
Subscribe to see PURGO SCIENTIFIC LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
PURGO SCIENTIFIC LLC is a medical devices company headquartered in United States. Its most recent funding round raised $3.5M in October 2023. Xcout tracks 10 named people at PURGO SCIENTIFIC LLC, including Dr. Cherice Roth (Chief Executive Officer).
4 more named people on record for PURGO SCIENTIFIC LLC, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $3.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of PURGO SCIENTIFIC LLC's closest competitors — see the full list of competitors and alternatives →
Colorado Therapeutics LLC is a medical device company that develops proprietary cross-linked tissue products and biologic implants for soft tissue repair. The company serves the medical and healthcare sector by providing advanced technological solutions for surgical applications.
Orthoson develops a micro-invasive bio-structural gel designed to treat lower back pain and degenerative disc disease by restoring the mechanical and biological function of intervertebral discs. The injectable treatment targets patients suffering from disc degeneration, aiming to provide immediate pain relief and restore a healthy disc environment.
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
Garwood Medical Devices, LLC develops technologies aimed at addressing bacterial biofilm infections related to medical implants. Their primary product under investigation is BioPrax, which is designed to help patients retain implants and improve infection control.
Reselute Medical develops therapeutic implant technologies for fracture management, specifically targeting orthopedic-related infections. Its primary product, the investigational Reselution Tibial Intramedullary Fixation System, combines structural bone fixation with sustained local antibiotic delivery in a single procedure for patients with severe fractures.
IlluminOss Medical is a commercial-stage medical device company that develops minimally invasive, photodynamic bone stabilization systems for fracture treatment.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.